Category

Archives

FGFR

Fibroblast growth factor (FGF), FGF receptor (FGFR), and cyclin D1 (CCND1) DNA methylation in head and neck squamous cell carcinomas is associated with transcriptional activity, gene amplification, human papillomavirus (HPV) status, and sensitivity to tyrosine kinase inhibitors

27 views | Jan 05 2022

Yilin Bao et al. found significant correlations of DNA methylation of specific CpG sites with response to the FGFR1/3-selective inhibitors PD 173074 and AZD4547, predominantly within the transcription start site of CCND1. [Read the Full Post]

Nintedanib Regulates GRK2 and CXCR2 to Reduce Neutrophil Recruitment in Endotoxin-Induced Lung Injury

273 views | Oct 02 2021

Vincent Yi-Fong Su et al. found that the inhibition of adhesion molecules via the activation of GRK2 and the inhibition of p38 MAPK and CXCR2. [Read the Full Post]

Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models

180 views | Sep 26 2021

Nicole J Chew et al. found the potential of specific FGFRs, including FGFR4, as targets for precision treatment. [Read the Full Post]

Targeted inhibition of FGF19/FGFR cascade improves antitumor immunity and response rate in hepatocellular carcinoma

188 views | Aug 26 2021

David Wai Meng Tai et al. suggested that HCC patients with high FGFR2/3 or FGF19/FGFR4 expressing tumors might benefit from a combination infigratinib/FGF401. [Read the Full Post]

Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study

190 views | Aug 26 2021

Milind Javle et al. found that infigratinib had promising clinical activity and a manageable adverse event profile in previously treated patients with locally advanced or metastatic cholangiocarcinoma harbouring FGFR2 gene fusions or rearrangements. [Read the Full Post]

Inhibition of AKR1B10-mediated metabolism of daunorubicin as a novel off-target effect for the Bcr-Abl tyrosine kinase inhibitor dasatinib

675 views | Aug 09 2021

Neslihan Büküm et al. demonstrated that dasatinib could synergize with Daun in human cancer cells and enhance its therapeutic effectiveness. [Read the Full Post]

Predictors of Response and Survival to Multikinase Inhibitors in Radioiodine Resistant Differentiated Thyroid Cancer

508 views | Aug 08 2021

Tiziana Feola et al. provided an overview of the predictive factors for the response and survival of sorafenib and lenvatinib in RR-DTC. [Read the Full Post]

Ivacaftor Inhibits Glioblastoma Stem Cell Maintenance and Tumor Progression

516 views | May 30 2021

Kun Liu et al. demonstrated that ivacaftor decreased stemness marker gene expressions of GSCs, including CD133, CD44, and Sox2. [Read the Full Post]

Paeoniflorin exerts antidepressant-like effects through enhancing neuronal FGF-2 by microglial inactivation

370 views | Apr 23 2021

Jie Cheng et al. found that paeoniflorin exhibited neuroprotective and antidepressant effects in mice, which might be mediated by activating neuronal FGF-2/FGFR1 signaling via the inhibition of microglial activation in the hippocampus. [Read the Full Post]

Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma

224 views | Apr 02 2021

Robert Hanes et al. supported LY2874455 as a better therapy than NVP-BGJ398 for FRS2-amplified liposarcoma, and a clinical trial was warranted. [Read the Full Post]